{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:20:57Z","timestamp":1789006857694,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Viatris"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Celecoxib is widely used for the management of different chronic musculoskeletal conditions including osteoarthritis (OA), but the comparative effectiveness of 200\u00a0mg once daily (OD) versus 100\u00a0mg twice daily (BID) in patients with varying baseline pain severity is not fully established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To compare the efficacy of celecoxib 200\u00a0mg OD and 100\u00a0mg BID in reducing pain among OA patients with moderate or severe baseline pain, using pooled post hoc analyses of two similar randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Data from two 6-week, double-blind, placebo-controlled trials in knee OA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,360) were pooled. Patients were stratified into moderate (VAS 40\u201369\u00a0mm,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009675) or severe (VAS\u2009\u2265\u200970\u00a0mm,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009685) pain subgroups. Interventions included celecoxib 100\u00a0mg BID, celecoxib 200\u00a0mg OD, or placebo. Primary endpoint was change from baseline in VAS pain at weeks 2 and 6, analyzed via mixed-effects model for repeated measures (MMRM) and ANCOVA with last observation carried forward. WOMAC pain score was a secondary endpoint.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both celecoxib regimens significantly reduced VAS pain scores versus placebo at weeks 2 and 6 in the overall and moderate pain groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). In severe pain patients, both regimens were superior to placebo at week 2; however, at week 6, only the 200\u00a0mg OD regimen retained statistical significance (LS mean difference vs. placebo \u2212\u20097.45,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0135), while 100\u00a0mg BID did not. WOMAC pain score results mirrored VAS findings, with 200\u00a0mg OD showing the greatest improvement in severe baseline pain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Celecoxib 100\u00a0mg BID and 200\u00a0mg OD are both effective for OA pain relief, in moderate and severe pain. Findings suggest 200\u00a0mg OD may confer an advantage in patients with severe baseline pain in the long-term treatment (week 6).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40520-025-03302-2","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:25:40Z","timestamp":1769189140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Different dosing regimens for chronic knee osteoarthritis (KOA) pain management: A pooled analysis on celecoxib"],"prefix":"10.1007","volume":"38","author":[{"given":"Ernest","family":"Choy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Fuggle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"Biesheuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar Suresh","family":"Kumbhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella Maria Rita","family":"Chiaese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-8965","authenticated-orcid":false,"given":"Chris","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"9","key":"3302_CR1","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","volume":"5","author":"GBD 2021 Osteoarthritis Collaborators","year":"2023","unstructured":"GBD 2021 Osteoarthritis Collaborators (2023) Lancet Rheumatol 5(9):e508 e522","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"3302_CR2","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/art.42089","volume":"74","author":"H Long","year":"2022","unstructured":"Long H, Liu Q, Yin H, Diao N, Zhang Y, Lin J et al (2022) Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019. Arthritis Rheumatol 74(7):1172\u20131183","journal-title":"Arthritis Rheumatol"},{"issue":"9783","key":"3302_CR3","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(11)60243-2","volume":"377","author":"JW Bijlsma","year":"2011","unstructured":"Bijlsma JW, Berenbaum F, Lafeber FP (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet 377(9783):2115\u20132126","journal-title":"Lancet"},{"issue":"1","key":"3302_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00482-018-0275-9","volume":"33","author":"K Mills","year":"2018","unstructured":"Mills K, H\u00fcbscher M, O\u2019Leary H et al (2018) Current concepts in joint pain in knee osteoarthritis. Schmerz 33(1):22\u201329","journal-title":"Schmerz"},{"issue":"5","key":"3302_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/rheumatology\/39.5.490","volume":"39","author":"P Creamer","year":"2000","unstructured":"Creamer P, Lethbridge-Cejku M, Hochberg MC (2000) Factors associated with functional impairment in symptomatic knee osteoarthritis. Rheumatology (Oxford) 39(5):490\u2013496","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"3302_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.joca.2013.03.018","volume":"21","author":"T Neogi","year":"2013","unstructured":"Neogi T (2013) The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage 21(9):1145\u20131153","journal-title":"Osteoarthritis Cartilage"},{"issue":"10289","key":"3302_CR7","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","volume":"397","author":"SP Cohen","year":"2021","unstructured":"Cohen SP, Vase L, Hooten WM (2021) Chronic pain: an update on burden, best practices, and new advances. Lancet 397(10289):2082\u20132097","journal-title":"Lancet"},{"issue":"15","key":"3302_CR8","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/eurjpc\/zwac127","volume":"29","author":"A-S R\u00f6nneg\u00e5rd","year":"2022","unstructured":"R\u00f6nneg\u00e5rd A-S, Nowak C, \u00c4ng B et al (2022) The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. Eur J Prev Cardiol 29(15):1994\u20132002","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"3302_CR9","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","volume":"27","author":"RR Bannuru","year":"2019","unstructured":"Bannuru RR, Osani MC, Vaysbrot EE et al (2019) OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 27(11):1578\u20131589","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"3302_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.semarthrit.2019.04.008","volume":"49","author":"O Bruy\u00e8re","year":"2019","unstructured":"Bruy\u00e8re O, Honvo G, Veronese N et al (2019) An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 49(3):337\u2013350","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"3302_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00124743-200004000-00002","volume":"6","author":"GW Williams","year":"2000","unstructured":"Williams GW, Ettlinger RE, Ruderman EM et al (2000) Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol 6(2):65\u201374","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"3302_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0149-2918(01)80004-7","volume":"23","author":"GW Williams","year":"2001","unstructured":"Williams GW, Hubbard RC, Yu SS et al (2001) Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 23(2):213\u2013227","journal-title":"Clin Ther"},{"issue":"5","key":"3302_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/rheumatology\/keh121","volume":"43","author":"K Stengaard-Pedersen","year":"2004","unstructured":"Stengaard-Pedersen K, Ekesbo R, Karvonen A-L et al (2004) Celecoxib 200\u00a0mg q.d. Is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing. Rheumatology (Oxford) 43(5):592\u2013595","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"3302_CR14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.1780290816","volume":"29","author":"R Altman","year":"1986","unstructured":"Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American Rheumatism Association. Arthritis Rheum 29(8):1039\u201349","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3302_CR15","first-page":"1833","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15(12):1833\u20131840","journal-title":"J Rheumatol"},{"issue":"8","key":"3302_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","volume":"140","author":"O STEINBROCKER","year":"1949","unstructured":"STEINBROCKER O, TRAEGER CH, BATTERMAN RC (1949) Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140(8):659\u2013662","journal-title":"J Am Med Assoc"},{"key":"3302_CR17","volume-title":"Dictionary of the rheumatic diseases","author":"American Rheumatism Association Glossary Committee","year":"1988","unstructured":"American Rheumatism Association Glossary Committee (1988) Dictionary of the rheumatic diseases, vol 1. Sign and Symptoms, New York. Contact Associates International Ltd."},{"key":"3302_CR18","unstructured":"Cohen B, Preuss CV Celecoxib. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535359\/"},{"key":"3302_CR19","doi-asserted-by":"crossref","unstructured":"Bensen WG, Fiechtner JJ, McMillen JI et al (1999) Treatment of Osteoarthritis With Celecoxib, a Cyclooxygenase-2 Inhibitor: A Randomized Controlled Trial. Mayo Clin Proc. ;74(11):1095\u20131105","DOI":"10.4065\/74.11.1095"},{"key":"3302_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/147323000102900602","volume":"29","author":"AJ Kivitz","year":"2001","unstructured":"Kivitz AJ, Moskowitz RW, Woods E et al (2001) Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 29:467\u2013479","journal-title":"J Int Med Res"},{"key":"3302_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/030097401750065265","volume":"30","author":"F McKenna","year":"2001","unstructured":"McKenna F, Borenstein D, Wendt H et al (2001) Celecoxib versus diclofenac in the management of osteoarthritis of the knee: A placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol 30:11\u201318","journal-title":"Scand J Rheumatol"},{"key":"3302_CR22","doi-asserted-by":"publisher","first-page":"10593","DOI":"10.1038\/srep10593","volume":"5","author":"C Zeng","year":"2015","unstructured":"Zeng C, Wei J, Li H et al (2015) Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Sci Rep 5:10593","journal-title":"Sci Rep"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-025-03302-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03302-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03302-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T02:00:37Z","timestamp":1769652037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-025-03302-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3302"],"URL":"https:\/\/doi.org\/10.1007\/s40520-025-03302-2","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EC has received support and\/or received grants and\/or a paid consultant and\/or received payment or honoraria and\/or is an editor of and\/or owns stocks and\/or recipient of miscellaneous services from Viatris, Pfizer, BioCancer, Sanofi, Abbvie, Biogen, Fresenius Kabi, Editor of Rheumatology (Oxford), and Inmedix. NF received payment or honoraria from Viatris, Amgen, and UCB. EB is an employee and owns stocks in Viatris. SV is an employee of Viatris. SSK is an employee of Viatris. RMRC is an employee of Viatris. CW is an employee of Viatris. JYR has received support and\/or a paid consultant and\/or received payment or honoraria and\/or received Support for attending meetings and\/or travel and\/or Participation on Advisory Board of Viatris. JYR is Deputy Editor of ACER but has not taken part in the assessment and publication process of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}}],"article-number":"55"}}